ZNF606

Summary

ZNF606 (zinc finger protein 606, HGNC:25879) is a protein-coding gene on chromosome 19q13.43, encoding Zinc finger protein 606 (Q8WXB4). May act as a transcriptional repressor.

This gene encodes a zinc finger protein containing a Kruppel-associated box (KRAB) domain at its N-terminus, followed by contiguous C2H2 zinc finger motifs. The encoded protein is a nuclear protein that can act as a transcriptional repressor of growth factor-mediated signaling pathways in a reporter gene assay. This protein has been shown to interact with the SRY-box 9 gene product, and suppresses its transcriptional activity by inhibiting its DNA binding activity. Reduced expression of this gene promotes chondrocyte differentiation. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 80095 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neuromyelitis optica (Limited, GenCC)
• Clinical variants (ClinVar): 107 total
• MANE Select transcript: NM_001348022

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25879
Approved symbol	ZNF606
Name	zinc finger protein 606
Location	19q13.43
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14260, KIAA1852
Ensembl gene	ENSG00000166704
Ensembl biotype	protein_coding
OMIM	613905
Entrez	80095

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000341164, ENST00000546715, ENST00000547121, ENST00000547828, ENST00000550560, ENST00000550599, ENST00000551380, ENST00000552184, ENST00000552579, ENST00000873329

RefSeq mRNA: 5 — MANE Select: NM_001348022 NM_001348022, NM_001348023, NM_001348024, NM_001348025, NM_025027

CCDS: CCDS12968

Canonical transcript exons

ENST00000551380 — 7 exons

Exon	Start	End
ENSE00001371743	57977076	57980279
ENSE00001383068	57999808	57999896
ENSE00002332357	58002396	58002820
ENSE00003493414	57988595	57988721
ENSE00003507370	57988207	57988302
ENSE00003630086	58001289	58001370
ENSE00003666296	58000683	58000739

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 91.94.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.8119 / max 54.2742, expressed in 1590 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182925	5.8119	1590

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	91.94	gold quality
right uterine tube	UBERON:0001302	88.77	gold quality
bronchial epithelial cell	CL:0002328	88.02	gold quality
epithelium of bronchus	UBERON:0002031	87.44	gold quality
ganglionic eminence	UBERON:0004023	87.15	gold quality
cortical plate	UBERON:0005343	86.63	gold quality
bronchus	UBERON:0002185	86.60	gold quality
ventricular zone	UBERON:0003053	86.40	gold quality
embryo	UBERON:0000922	84.91	gold quality
right lobe of thyroid gland	UBERON:0001119	83.88	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.77	gold quality
left lobe of thyroid gland	UBERON:0001120	82.91	gold quality
thyroid gland	UBERON:0002046	82.65	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.49	gold quality
mucosa of paranasal sinus	UBERON:0005030	81.63	gold quality
calcaneal tendon	UBERON:0003701	81.55	gold quality
left ovary	UBERON:0002119	81.54	gold quality
oocyte	CL:0000023	81.41	gold quality
sperm	CL:0000019	81.03	gold quality
right ovary	UBERON:0002118	80.98	gold quality
tibia	UBERON:0000979	80.96	gold quality
pigmented layer of retina	UBERON:0001782	80.90	gold quality
ovary	UBERON:0000992	80.74	gold quality
germinal epithelium of ovary	UBERON:0001304	80.64	gold quality
middle temporal gyrus	UBERON:0002771	80.48	gold quality
adenohypophysis	UBERON:0002196	80.36	gold quality
pituitary gland	UBERON:0000007	80.32	gold quality
choroid plexus epithelium	UBERON:0003911	80.29	gold quality
epithelial cell of pancreas	CL:0000083	80.07	silver quality
male germ cell	CL:0000015	79.96	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.35

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

58 targeting ZNF606, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-1290	99.59	69.90	2079
HSA-MIR-6758-3P	99.57	67.55	1078
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-7849-3P	99.47	68.17	1224
HSA-MIR-508-5P	99.41	64.25	1248
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-29A-5P	99.08	68.59	1813
HSA-MIR-628-3P	99.04	68.37	814

Literature-anchored findings (GeneRIF, showing 3)

• results suggest that ZNF328 protein may act as a transcriptional repressor in mitogen-activated protein kinase (MAPK) signaling pathway to mediate cellular functions (PMID:15964554)
• ZNF606 prevents Sox9 binding to the enhancers of its target gene col2a1. Importantly, the interaction between ZNF606 and Sox9 was decreased during chondrocyte differentiation. (PMID:27634221)
• findings suggest that it is novel and specific for the association of ZNF606 gene expression from monocytes with the risk of CAD, especially in patients with multiple coronary artery stenosis (PMID:30130524)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp606	ENSMUSG00000030386

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 606 — Q8WXB4 (reviewed: Q8WXB4)

Alternative names: Zinc finger protein 328

All UniProt accessions (6): Q8WXB4, F8VVX5, F8VZC9, F8VZG6, F8W1C8, F8W1H2

UniProt curated annotations — full annotation on UniProt →

Function. May act as a transcriptional repressor.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed in adult and fetal tissues.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (5): NP_001334951, NP_001334952, NP_001334953, NP_001334954, NP_079303 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (20 total): zinc finger region 16, chain 1, domain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WXB4-F1	59.56	0.04

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 70 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, GSE45365_NK_CELL_VS_CD8_TCELL_DN, GSE45365_NK_CELL_VS_CD11B_DC_UP, TCCAGAG_MIR518C, WALLACE_PROSTATE_CANCER_RACE_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP, VERHAAK_GLIOBLASTOMA_CLASSICAL, ZNF711_TARGET_GENES, ZNF92_TARGET_GENES, MIR5582_3P, MIR4659A_3P_MIR4659B_3P, MIR4668_5P, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2, MIR3924

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (3): DNA binding (GO:0003677), zinc ion binding (GO:0008270), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
nucleic acid binding	1
transition metal ion binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

564 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF606	C5orf47	Q569G3	479
ZNF606	FAM194C	Q8ND61	447
ZNF606	OR10S1	Q8NGN2	447
ZNF606	KIAA1958	Q8N8K9	424
ZNF606	RTL8A	Q9BWD3	374
ZNF606	PRMT2IP	Q6ZRI6	370
ZNF606	TMEM248	Q9NWD8	350
ZNF606	C2CD4C	Q8TF44	323
ZNF606	TTC38	Q5R3I4	317
ZNF606	SUGP2	Q8IX01	300
ZNF606	RNF157	Q96PX1	298
ZNF606	DISP3	Q9P2K9	290
ZNF606	CCDC85A	Q96PX6	290
ZNF606	TEX2	Q8IWB9	289
ZNF606	TRIL	Q7L0X0	289

IntAct

6 interactions, top by confidence:

A	B	Type	Score
	ZNF606	psi-mi:“MI:0915”(physical association)	0.370
EPHA1	ZNF606	psi-mi:“MI:0915”(physical association)	0.000
APP	ZNF606	psi-mi:“MI:0915”(physical association)	0.000
RBM11	ZNF606	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (10): ZNF606 (Affinity Capture-MS), ZNF606 (Affinity Capture-RNA), ZNF606 (Affinity Capture-MS), ZNF606 (Two-hybrid), ZNF606 (Two-hybrid), ZNF606 (Co-fractionation), ZNF606 (Co-fractionation), ZNF606 (Co-fractionation), ZNF606 (Co-fractionation), ZNF606 (Co-fractionation)

ESM2 similar proteins: A0A087WUV0, A0JNB1, A2VDP4, B2RUI1, P0CG31, P10072, P17025, P17036, P17097, P18733, P51814, Q08ER8, Q09FC8, Q0VGE8, Q14590, Q15937, Q16600, Q2M3X9, Q4V8A8, Q5CZA5, Q5R8G9, Q5RBX0, Q5VIY5, Q68DI1, Q6J6I6, Q6NX49, Q6P1L6, Q6PG37, Q6ZMS4, Q6ZMW2, Q80YP6, Q86UD4, Q86Y25, Q8IZ26, Q8N184, Q8NB42, Q8NEK5, Q8TAF7, Q8TF47, Q8WXB4

Diamond homologs: A0A1W2PQL4, A0JNB1, A0JPL0, A6NK53, A6QLU5, A6QPT6, A7MBI1, A8MT65, A8MUV8, A8MWA4, B2RXC5, B4DU55, B4DX44, E9PYI1, O14628, O75346, P0CH99, P0CI00, P17014, P17030, P17032, P17098, P51786, P85977, Q02386, Q06730, Q06732, Q0VAW7, Q12901, Q13360, Q14586, Q14588, Q14590, Q16587, Q2M3X9, Q2VY69, Q32M78, Q3ZCX4, Q49AA0, Q4R6J4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	94
Likely benign	3
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

981 predictions. Top by Δscore:

Variant	Effect	Δscore
19:57980278:TT:T	acceptor_gain	1.0000
19:57980280:C:CC	acceptor_gain	1.0000
19:57988302:CC:C	acceptor_loss	1.0000
19:57988302:CCTA:C	acceptor_gain	1.0000
19:57988303:C:CA	acceptor_loss	1.0000
19:57988305:A:C	acceptor_gain	1.0000
19:57988308:CA:C	acceptor_gain	1.0000
19:57988309:A:C	acceptor_gain	1.0000
19:57988593:A:AC	donor_gain	1.0000
19:57988593:AC:A	donor_gain	1.0000
19:57988594:C:CC	donor_gain	1.0000
19:57988594:CC:C	donor_gain	1.0000
19:57988594:CCCA:C	donor_gain	1.0000
19:57980275:CCATT:C	acceptor_gain	0.9900
19:57980276:CATT:C	acceptor_gain	0.9900
19:57980276:CATTC:C	acceptor_gain	0.9900
19:57988201:CCTCA:C	donor_loss	0.9900
19:57988202:CTCAC:C	donor_loss	0.9900
19:57988203:TCA:T	donor_loss	0.9900
19:57988205:ACC:A	donor_loss	0.9900
19:57988206:CCTG:C	donor_loss	0.9900
19:57988230:G:A	donor_gain	0.9900
19:57988299:TTTC:T	acceptor_gain	0.9900
19:57988300:TTC:T	acceptor_gain	0.9900
19:57988301:TC:T	acceptor_gain	0.9900
19:57988303:C:CC	acceptor_gain	0.9900
19:57988305:A:AC	acceptor_gain	0.9900
19:57988309:A:AC	acceptor_gain	0.9900
19:57988589:CCT:C	donor_loss	0.9900
19:57988591:TTA:T	donor_loss	0.9900

AlphaMissense

3404 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:57979201:G:C	F493L	1.000
19:57979201:G:T	F493L	1.000
19:57979203:A:G	F493L	1.000
19:57979184:A:G	L499P	0.999
19:57979285:G:C	F465L	0.999
19:57979285:G:T	F465L	0.999
19:57979287:A:G	F465L	0.999
19:57979162:A:C	H506Q	0.998
19:57979162:A:T	H506Q	0.998
19:57979174:A:C	H502Q	0.998
19:57979174:A:T	H502Q	0.998
19:57979176:G:C	H502D	0.998
19:57979202:A:G	F493S	0.998
19:57979203:A:T	F493I	0.997
19:57979224:A:G	C486R	0.997
19:57979168:C:A	R504S	0.996
19:57979168:C:G	R504S	0.996
19:57979172:T:G	Q503P	0.996
19:57979268:A:G	L471P	0.996
19:57979286:A:G	F465S	0.996
19:57979337:C:G	R448P	0.996
19:57979164:G:C	H506D	0.995
19:57979176:G:T	H502N	0.995
19:57979246:A:C	H478Q	0.995
19:57979246:A:T	H478Q	0.995
19:57979175:T:C	H502R	0.994
19:57979203:A:C	F493V	0.994
19:57979222:A:C	C486W	0.994
19:57979230:A:C	Y484D	0.994
19:57979260:G:C	H474D	0.994

dbSNP variants (sampled 300 via entrez): RS1000007153 (19:57996328 CCT>C), RS1000313862 (19:58003253 C>T), RS1000491496 (19:57988389 C>G), RS1000492626 (19:57990531 C>T), RS1000705176 (19:57983154 T>C), RS1000728691 (19:57980924 T>A), RS1000774066 (19:57988718 G>C), RS1000812924 (19:57981249 G>A), RS1001003786 (19:57994455 T>C), RS1001074214 (19:57994258 C>T), RS1001075480 (19:58000321 A>T), RS1001076716 (19:57982845 C>T), RS1001164428 (19:57986082 T>A,C), RS1001254833 (19:58000802 C>A), RS1001266483 (19:58004719 C>T)

Disease associations

OMIM: gene MIM:613905 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neuromyelitis optica	Limited	Autosomal dominant

Mondo (1): neuromyelitis optica (MONDO:0019100)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009471	Neuromyelitis Optica	C10.114.375.600.500; C10.114.375.800; C10.292.700.550.500; C10.314.350.600.500; C10.314.350.800; C11.640.576.695; C20.111.258.250.550.500; C20.111.258.250.775

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation	4
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
geraniol	increases expression	1
arsenite	increases methylation	1
sodium arsenite	increases expression	1
ferrous chloride	decreases expression	1
avobenzone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
jinfukang	decreases expression	1
(+)-JQ1 compound	increases response to substance	1
Temozolomide	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects methylation	1
Atrazine	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Nickel	decreases expression	1
Phthalic Acids	decreases methylation	1
Potassium Chloride	decreases expression, decreases response to substance	1
Silicon Dioxide	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Dronabinol	decreases expression, decreases response to substance	1
Thiram	increases expression	1

Clinical trials (associated diseases)

117 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00304291	PHASE4	COMPLETED	A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)
NCT02021825	PHASE4	UNKNOWN	Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
NCT02809079	PHASE4	UNKNOWN	Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
NCT04256252	PHASE4	COMPLETED	Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)
NCT05269667	PHASE4	TERMINATED	A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
NCT06180278	PHASE4	ACTIVE_NOT_RECRUITING	Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT06212245	PHASE4	UNKNOWN	A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
NCT01892345	PHASE3	TERMINATED	A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
NCT02003144	PHASE3	COMPLETED	An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
NCT02028884	PHASE3	COMPLETED	Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
NCT02073279	PHASE3	COMPLETED	Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT02398994	PHASE3	TERMINATED	A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
NCT03330418	PHASE3	TERMINATED	A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
NCT04201262	PHASE3	COMPLETED	An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
NCT04660539	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05199688	PHASE3	RECRUITING	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05314010	PHASE3	ACTIVE_NOT_RECRUITING	A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05730699	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
NCT06724809	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
NCT07132398	PHASE3	NOT_YET_RECRUITING	Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD
NCT07557420	PHASE3	NOT_YET_RECRUITING	Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT00716066	PHASE2	ACTIVE_NOT_RECRUITING	Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
NCT01845584	PHASE2	COMPLETED	Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
NCT02166346	PHASE2	COMPLETED	Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
NCT02249676	PHASE2	COMPLETED	Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
NCT02893111	PHASE2	COMPLETED	Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
NCT04064944	PHASE2	UNKNOWN	Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
NCT04614454	PHASE2	COMPLETED	High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
NCT04670770	PHASE2	COMPLETED	An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
NCT05356858	PHASE2	TERMINATED	An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
NCT05549258	PHASE2	RECRUITING	Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
NCT05551598	PHASE2	COMPLETED	Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT06497374	PHASE2	NOT_YET_RECRUITING	FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
NCT06697535	PHASE2	RECRUITING	A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
NCT00501748	PHASE1	COMPLETED	Safety and Tolerability of Rituximab in Neuromyelitis Optica
NCT01759602	PHASE1	COMPLETED	C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
NCT01777412	PHASE1	COMPLETED	Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
NCT02087813	PHASE1	WITHDRAWN	Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
NCT02276963	PHASE1	COMPLETED	Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
NCT02283671	PHASE1	COMPLETED	Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B